EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 20-Jun-2026 12:15 ET (20-Jun-2026 16:15 GMT/UTC)

15-Jun-2026

Large-scale European study shows that prevention in patients with inherited cancer risks produces substantial cost benefits

European Society of Human Genetics
Reports and Proceedings

The cost of screening people with the rare, inherited cancer-causing condition Li-Fraumeni syndrome (LFS) is roughly nine times lower than that of treatment, researchers have found. This evidence is sufficient to make the case for investing in early genetic testing in tumour risk syndromes, they say, with benefits not just for patients, but also for healthcare systems.

15-Jun-2026

Secondhand smoke can leave cancer-causing cadmium in the body

Texas A&M University
Peer-Reviewed Publication

A new study finds that adults who simply breathe in secondhand cigarette smoke have about 1.5 times more of the toxin cadmium in their blood than people in smoke-free environments.

Journal: Biological Trace Element Research

15-Jun-2026

Johns Hopkins Medicine receives $10 million gift to advance urological surgery

Johns Hopkins Medicine
Grant and Award Announcement

The James Buchanan Brady Urological Institute at Johns Hopkins Medicine has a newly endowed division, called the Robert Altman Division of Minimally Invasive Surgery, following a $10 million gift from the Robert and Lynda Altman Family Foundation. The gift supports ongoing research, education and care to support the world-renowned center, which provides less-invasive surgical care to patients of all ages presenting with a range of urological conditions.

15-Jun-2026

Weill Cornell Medicine scientist receives award for research on new ovarian cancer targets

Weill Cornell Medicine
Grant and Award Announcement

Dr. Dan Landau, the Bibliowicz Family Professor of Medicine, and a member of the Sandra and Edward Meyer Cancer Center and the Englander Institute for Precision Medicine at Weill Cornell Medicine, has received a Lotus Award from the Pershing Square Foundation for research aimed at uncovering new immunotherapy targets in ovarian cancer.

15-Jun-2026

New breakthrough in developing more personalized treatments for lung cancer

University of Barcelona
Peer-Reviewed Publication

A study by the University of Barcelona has discovered why the two main types of lung cancer — adenocarcinoma of the lung and squamous cell carcinoma — respond differently to anti-angiogenic therapy, that is, drugs that block the formation of new blood vessels that tumours need in order to grow. The results, published in the journal CCell Death & Disease, show that these differences largely depend on the environment surrounding the tumours, particularly on some very abundant benign cells called fibroblasts. This finding opens the door to the development of more personalized therapies, tailored to the specific characteristics of each tumour’s microenvironment.

Journal: Cell Death and Disease

15-Jun-2026

Some immune cells can limit the effect of cancer immunotherapy

Karolinska Institutet
Peer-Reviewed Publication

A type of white blood cell in the immune system, known as neutrophils, can make cancer immunotherapy less effective. This is shown in a new study from Karolinska Institutet published in the journal Immunity. The results show that a signalling molecule in the tumour affects neutrophils, reducing the effect of treatment.

Journal: Immunity

15-Jun-2026

Researchers identify target with potential to improve CAR T-cell therapy response in patients with blood cancers

University of Maryland School of Medicine
Peer-Reviewed Publication

University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.

In a recent study published in Signal Transduction and Targeted Therapy, scientists found increased survival and tumor-fighting activity in lab and animal models when they blocked a specific protein in the modified cells.

Journal: Signal Transduction
Funder: Maryland Department of Health and Mental Hygiene

15-Jun-2026

Immune activation may determine success of dual-target CAR T therapy in glioblastoma

University of Pennsylvania School of Medicine
Peer-Reviewed Publication

Dual-target CAR T cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes and longer overall survival. CSF of individuals who did not respond to the therapy exhibited a higher proportion of activated regulatory T cells (Tregs) and high baseline levels of immunosuppressive scavenger myeloid cells.

Journal: Cell
Funder: Kite, a Gilead Company, French National Cancer Institute, Ministry of Health and Prevention, Inserm Transfert, American Cancer Society

15-Jun-2026

HPV therapeutic vaccine shows safety but uncertain benefit in preventing head and neck cancer recurrence

Impact Journals LLC
Peer-Reviewed Publication

BUFFALO, NY – June 15, 2026 – A new research paper was published in Volume 17 of Oncotarget on June 5, 2026, titled “A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence.”

Journal: Oncotarget

15-Jun-2026

New treatment combination delays multiple myeloma progression and may improve survival, study finds

Wake Forest University School of Medicine
Peer-Reviewed Publication

Patients with relapsed multiple myeloma lived significantly longer without disease progression and showed early survival gains in a global phase 3 trial of a talquetamab-based immunotherapy combo, offering new hope for improved treatment outcomes.

Journal: New England Journal of Medicine
Funder: Janssen Biotech